(Q44816559)

6 December 2017

title

Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer (English)

1 reference

6 December 2017

1 reference

6

Dennis S Chi

1 reference

6 December 2017

4

Carol Aghajanian

1 reference

6 December 2017

Monica Prasad

1

1 reference

6 December 2017

Leah Ben-Porat

2

1 reference

6 December 2017

Brad Hoppe

3

1 reference

6 December 2017

Paul Sabbatini

5

1 reference

6 December 2017

Martee L Hensley

7

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

93

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

223-228

1 reference

6 December 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Weekly topotecan in the management of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.01.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2004.01.014

1 reference

6 December 2017

1 reference